
Medically Reviewed By
Dr. Neha Gupta ( Medical Oncology)
A clinical immunotherapy manual on dual checkpoint blockade (Nivolumab + Ipilimumab) in metastatic RCC and MSI-H/dMMR colorectal malignancies, detailing synergistic T-cell priming and steroid algorithms for irAE management.
CRITICAL CLINICAL RED FLAG: Any severe non-infectious diarrhea (>4-6 stools/day over baseline), acute transaminitis (ALT/AST >3x ULN), or morning hypotension and profound fatigue (Hypophysitis/Adrenal Insufficiency) in patients on dual checkpoint inhibitors warrants immediate steroid initiation and endocrine workup.
Dual immune checkpoint blockade harnesses two distinct, complementary phases of antitumor immunity: Anti-CTLA-4 (Ipilimumab) promotes de novo T-cell priming and clonal expansion within regional lymph nodes, while Anti-PD-1 (Nivolumab) rejuvenates exhausted effector T-cells in the tumor microenvironment. This dual mechanism produces deep, durable complete responses in tumors historically refractory to conventional chemotherapy.
Advanced Renal Cell Carcinoma (CheckMate-214): Delivers an overall survival advantage over Sunitinib in intermediate/poor-risk RCC with complete response rates exceeding 12%.
MSI-H / dMMR Colorectal Cancer (CheckMate-142): Produces objective response rates of 65% and 24-month progression-free survival rates of 74% in metastatic mismatch repair-deficient colorectal tumors.
Dual checkpoint blockade carries an elevated incidence of grade 3/4 immune toxicities (~55%). Early recognition and standardized management prevent life-threatening organ damage:
Immune Colitis (Grade 2+): Hold immunotherapy; start oral Prednisolone 1 mg/kg/day. For refractory cases within 48–72 hours, administer Infliximab (5 mg/kg) or Vedolizumab.
Immune Hypophysitis / Adrenal Crisis: Check ACTH, morning Cortisol, TSH, Free T4. Replace physiological Hydrocortisone (15–20 mg/day) and Levothyroxine before resuming therapy.
Immune Hepatitis: Rule out viral etiology; initiate high-dose steroids (Prednisolone 1–2 mg/kg/day). Note: Infliximab is contraindicated in severe immune hepatitis due to hepatotoxicity risk (use Mycophenolate Mofetil).
"The hallmark of immunotherapy is treatment durability. Mastering the management of immune-related toxicities ensures patients achieve lifelong disease control safely." — Dr. Neha Gupta
1. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (CheckMate-214). New England Journal of Medicine (NEJM), 2018; 378: 1277-1290.
2. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer (CheckMate-142). J Clin Oncol, 2018; 36(8): 773-779.
3. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol, 2021; 39(36): 4073-4126.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi

13+ Years Experience
Spica — Grover Hospital
Request a priority OPD appointment or second opinion on your scans.
Proprietary surgical methodologies and precision protocols pioneered by our senior directors to minimize trauma, protect natural anatomy, and accelerate recovery.

Dr. Deepak Garg (Orthopaedic Surgical Oncology - RGCI Delhi Trained) and Dr. Neha Gupta (Medical Oncology) co-lead the Bone Cancer & Sarcoma Center at Spica Healthcare. Integrating intensive multi-agent neoadjuvant chemotherapy protocols (MAP: High-Dose Methotrexate, Doxorubicin, Cisplatin for Osteosarcoma; VIDE: Vincristine, Ifosfamide, Doxorubicin, Etoposide for Ewing Sarcoma) with 3D computer-navigated limb salvage surgery and modular titanium megaprosthetic joint reconstruction, 5-year survival rates exceed 75% to 80% while saving over 95% of patients from limb amputation.
Spica Healthcare — Bone and Cancer Institute, Bathinda — is South-Western Punjab's premier super-speciality centre led by AIIMS and Tata Memorial fellowship-trained directors.
Every diagnostic MRI review, surgical staging, and operation is personally directed by chief clinical specialists — Dr. Deepak Garg (Orthopaedic Oncology & Robotics) and Dr. Neha Gupta (Medical Oncology) — guaranteeing zero junior proxies.
Sub-millimeter implant positioning and soft-tissue ligament balancing ensuring patients walk comfortably within 24 hours of total knee replacement.
South-West Punjab's only dedicated centre for modular titanium megaprosthesis, saving natural limbs and functions in 95%+ of bone cancer patients.
Full cashless coverage for Ayushman Bharat (PM-JAY), Punjab Govt Health Schemes, ECHS, and 30+ private insurance networks with on-desk approvals.
Positive-pressure HEPA filtered theatres minimizing infection rates below international benchmarks with 24/7 dedicated critical care backup.
Fellowship-trained surgical directors from AIIMS & Tata Memorial providing compassionate, world-class tertiary care in super-speciality orthopaedics and medical oncology.

Senior Consultant & Clinical Director — Medical Oncology
MBBS (BFUHS Faridkot), MD Radiation Oncology (BFUHS Faridkot), DrNB Medical Oncology (Sarvodaya Hospital, Faridabad), Precision Oncology (Harvard, USA), Ex Consultant RGCI New Delhi


Senior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
16+ Yrs ExpSenior Consultant & Clinical Director — Orthopaedic Oncology & Robotic Joint Surgery
MBBS (TNMC Mumbai), DNB Orthopaedics (PGI & SP Miraj), Fellowship Arthroplasty and Arthroscopy (Fortis Hospital, New Delhi), Fellowship Orthopaedic Oncology (Rajiv Gandhi Cancer Institute, New Delhi)
Free OPD screening camps, director-led masterclasses, and national oncology representations by Spica Healthcare.
Real stories from patients who recovered through limb preservation surgery, 3D robotic joint replacements, and precision cancer care at Spica Healthcare — Grover Hospital, Bathinda.
Evidence-based surgical recovery roadmaps, robotic joint protocols, and precision oncology insights written by our clinical directors.